For decades, treating brain cancer and central nervous system (CNS) disorders has been one of medicine’s toughest battles, largely because of the blood-brain barrier (BBB)—a natural defense that blocks most therapies from reaching the brain. While this barrier protects the brain, it also limits treatment options, leaving patients with few solutions and diminished hope. Today, advancements in biotechnology are changing that narrative, opening doors to non-invasive, targeted therapies that can overcome these limitations and deliver life-changing results.
NeOnc Technologies Holdings, Inc., is a clinical-stage life-sciences company focused on the development of innovative solutions for how we approach CNS diseases and brain cancer. Focused on the development of its innovative NEO-100 intranasal delivery platform, NeOnc Technologies is involved in the development of a method designed to bypass the BBB so that therapies reach the brain where they are needed most. NeOnc Technologies’s commitment is to deliver hope through innovation and work towards offering solutions that are effective and life-changing.
The Visionary Beginnings of NeOnc Technologies
NeOnc Technologies was founded on the visionary work of Dr. Chen, Founder, and Scientist, whose deep expertise in oncology and neuroscience led to a mission to solve one of medicine’s greatest challenges: delivering effective therapies across the blood-brain barrier. Dr. Chen’s research at USC Keck Medical School highlighted the potential to address critical unmet needs for patients with CNS diseases and brain cancer. This dedication to innovation continues to drive NeOnc Technologies’s mission to develop life-changing solutions and to offer hope where few treatment options exist.
Overcoming the Blood-Brain Barrier
The blood-brain barrier (BBB) presents a significant challenge for traditional therapies, as its selective nature prevents many treatments from reaching the brain in effective concentrations. This limitation has made it difficult to address brain disorders with conventional methods, reducing their overall effectiveness. NeOnc Technologies has responded to this issue with NEO-100, a development-stage platform that designed to bypasses the BBB safely, allowing therapeutic agents to reach their targets in the brain.
NEO-100 is made from a proprietary synthesis of Perillyl Alcohol (POH), which research suggests may have beneficial effects for treating CNS diseases. These include.
Potentially acting as a regulator for neurological pathways associated with tumor cell growth.
When delivered intranasally, its small molecular size allows it to bypass the BBB.
When delivered intra-arterially, it can temporarily open the BBB, allowing larger molecule therapeutics to pass through.
In high concentrations, NEO-100 may be a treatment for brain cancers.
In lower concentrations, it may serve as a solvent for traditional large-molecule therapeutics, potentially helping them cross the BBB.
It may potentially be conjugated with other CNS therapeutics to create compound formulations that may be used to enhance BBB penetration and improve brain cancer treatment.
With its first-mover advantage and a strong intellectual property portfolio protecting its innovations, NeOnc Technologies is paving the way for potential new treatment options that were once thought impossible.
NeOnc Technologies’s Progress in Clinical Trials
NeOnc Technologies is making significant progress with its innovative therapies in clinical trials, advancing toward potential solutions for brain cancer and CNS disorders. The company’s commitment to groundbreaking research is demonstrated by ongoing Phase I and Phase II trials that are paving the way for new treatment options for patients.
Intellectual Property Protection: A robust portfolio safeguarding NeOnc’s innovations.
Clinical Trial Progress: Ongoing Phase I and Phase II trials, reflecting the company’s commitment to transform early-stage research into viable patient solutions.
Revolutionizing CNS Treatment
The Company’s development-stage NEO-100 intranasal delivery system is designed to offer a solution to CNS disorders by bypassing the BBB and delivering higher concentrations of therapeutic agents directly to the brain. Unlike traditional therapies, NEO-100 can potentially offer a non-invasive, precision-focused method for treatment of brain cancer and other CNS conditions,
Expanding Drug Delivery Beyond the BBB
NeOnc Technologies is focused on advancing its clinical trials and expanding the use of NEO-100 to benefit a broader range of patients. The company is also exploring new potential applications for its intranasal platform.
With a strong first-mover advantage and solid intellectual property protection, the company believes it is well-positioned to offer potential solutions in the next phase of CNS therapeutics.
Innovation and Regulatory Challenges in Biotech
Balancing innovation with regulatory compliance requires a proactive approach. NeOnc works closely with regulatory bodies, while its strong intellectual property portfolio supports ongoing innovation.
Dr. Chen’s commitment to scientific research, along with a team focused on patient outcomes, ensures that NeOnc Technologies continues to prioritize the development of transformative therapies, even when navigating complex regulatory challenges.
Advice for Life Sciences Innovators
Amir’s advice is to embrace bold thinking and persistence. Overcoming barriers like the BBB requires a strong commitment to innovation and the ability to navigate challenges. He emphasizes the importance of building a strong team, fostering collaboration, and safeguarding intellectual property with a solid patent strategy. Amir’s core belief is simple: patients must always be at the heart of the mission, with the ultimate goal being to transform and improve their lives.
The Future of Brain-Targeted Drug Delivery Technology
The future of brain-targeted drug delivery is focused on precision, non-invasive methods, and the integration of advanced technologies. In the coming years, it is hoped that barriers like the BBB will no longer limit treatment options, opening new opportunities for patients with CNS diseases.
With NEO-100, NeOnc Technologies believes it is well-positioned to drive this transformation. With its strong portfolio, the company is working toward a future where CNS diseases are treatable and potentially curable.
